NSE: SANOFI | BSE: 500674

Mid-range Performer

Download real time

5037.50 0.50 (0.01%)

Near 52W Low of ₹4902.00

14,999 NSE+BSE Volume

NSE 19 Sep, 2025 3:31 PM (IST)

11,601.7

Market Cap

High in industry

0.4

Beta 1Year

Very Low volatility

Sanofi India Ltd. share price target and research reports

Name: Latest research reports of Sanofi India Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Sanofi India Ltd.
Rating: 5
Author: ICICI Securities Limited

Latest analyst research reports with target prices and PDF download for SANOFI, BSE:500674 Sanofi India Ltd.

Sanofi India Ltd.

18 Dec 2017

5037.50

0.01%

Sanofi India

Buy: Sanofi India Ltd.

ICICI Securities Limited

Sanofi India Ltd. is trading below all available SMAs

Sanofi India Ltd.

20 Nov 2017, 12:00AM

5037.50

0.01%

Result Updates

Neutral: Sanofi India Ltd.

Angel Broking

For 3QCY2017, Sanofi India posted results which were above expectations on all fronts. The sales came in at `627cr v/s. `590cr expected, registering a yoy growth of 5.0%. On the operating front, the EBITDA margin came in at 22.8% (15.7% expected) v/s. 17.6% in 3QCY2016. GPM (Gross Profit Margin) was better at 50.5% v/s. 48.3% in 3QCY2016,..

Sanofi India Ltd. is trading below all available SMAs

Sanofi India Ltd.

01 Nov 2017

5037.50

0.01%

Sanofi India

Buy: Sanofi India Ltd.

Centrum Broking

Revenue grew by 5%YoY: SIL's revenue grew 5%YoY to Rs6.67bn from Rs6.38bn and was impacted by uncertainties of GST launch. The company's top 18 brands contributed ~70% to revenues. Twelve of the 18 top brands surpassed the market growth rate of 2.8% in September'17. We expect these brands to drive the company's growth. SIL derives ~27% of its revenues from exports of APIs, formulations and insulin pens. Launch of new products and line extensions, volume growth of existing brands would drive future growth. EBIDTA margin improved by 460bps: SIL's EBIDTA margin improved by 460bps to...

Sanofi India Ltd. is trading below all available SMAs

Sanofi India Ltd.

31 Oct 2017

5037.50

0.01%

Sanofi India: Strong recovery in margin

Buy: Sanofi India Ltd.

Target

Motilal Oswal

Sanofi's (SANL) 3QCY17 revenue increased ~7% YoY (+11% QoQ) to INR6.7b (~3.4% miss). EBITDA rose 27% YoY to INR1.8b (+21% beat), as margins expanded ~440bp YoY (+830bp QoQ) to 27.5%. Consequently, PAT increased sharply by 44% YoY to INR1.2b (31% beat). High-single-digit revenue growth, coupled with strong margin: According to AIOCD, secondary sales growth for SANL stood at ~6% YoY, higher than industry, which saw flattish growth of 1%. The company's key therapeutic areas posted strong growth during the quarter: Anti-Diabetic portfolio grew...

Sanofi India Ltd. has lost -29.82% in the last 1 Year

Sanofi India Ltd.

28 Aug 2017

5037.50

0.01%

Result Updates

Neutral: Sanofi India Ltd.

Angel Broking

For 2QCY2017, Sanofi India posted results which were below expectations on all fronts. The sales came in at `556cr v/s. `520cr expected, registering a yoy de-growth of 3.8%. On the operating front, the EBITDA margin came in at 12.7% (17.6% expected) v/s. 18.6% in 2QCY2016. Despite better GPM (Gross Profit Margin), which came in at 55.5% v..

Sanofi India Ltd. has lost -29.82% in the last 1 Year

Sanofi India Ltd.

20 Jul 2017, 11:00AM

5037.50

0.01%

Sanofi India Ltd Q2CY17 results comment

Results Update: Sanofi India Ltd.

HDFC Securities

Sanofi India Ltd Q2CY17 results comment Revenue rose by 8.41% to Rs. 555.8 Cr in Q2CY17 when compared to the previous quarter.

Sanofi India Ltd. is trading below all available SMAs

Sanofi India Ltd.

09 May 2017

5037.50

0.01%

Result Updates

Neutral: Sanofi India Ltd.

Angel Broking

For 1QCY2017, Sanofi India posted results which were below expectations on all fronts. The sales came in at `513cr v/s. `550cr expected, registering a yoy de-growth of 1.1%. On the operating front, the EBITDA margin came in at 12.0% (17.6% expected) v/s. 17.7% in 1QCY2016. Despite better GPM (Gross Profit Margin), which came in at 54.2% v..

Sanofi India Ltd. is trading below all available SMAs

Sanofi India Ltd.

10 Mar 2017

5037.50

0.01%

Result Updates

Neutral: Sanofi India Ltd.

Angel Broking

For 4QCY2016, Sanofi India posted results which were below expectations on the sales front. The sales came in at Rs552cr v/s. Rs570cr expected, posting a yoy growth of 5.6%. On the operating front, the EBITDA margin came in at 12.2% (12.3% expected) v/s. 12.7% in 4QCY2015. This came in-spite of GPM (Gross Profit Margin), which came in at ..

Sanofi India Ltd. has lost -29.82% in the last 1 Year

Is Sanofi India Ltd. worth buying?

295 Votes:

Buy 79.66%

Sell 11.19%

Hold 9.15%